Yuyu Pharma to Attend ‘CPHI Worldwide 2023’ in Barcelona, Spain
Yuyu Pharma, a leading global pharmaceutical company based in Seoul, South Korea, is gearing up to participate in the highly anticipated CPHI Worldwide event taking place in Barcelona, Spain. The event is scheduled to run from October 24th to October 26th, providing a platform for Yuyu Pharma to showcase its cutting-edge products and establish valuable partnerships.
Yuyu Pharma, known for its 80 years of excellence in the healthcare industry, is dedicated to developing innovative therapeutics in various fields, including neurology, dermatology, urology, and ophthalmology. As part of its commitment to enhancing healthcare and improving the quality of life for individuals worldwide, the company is set to unveil its latest products and projects at the CPHI Worldwide 2023 exhibition.
Visitors to the event will have the opportunity to meet the Yuyu Business Development team at booth #7G30 within the Korean Trade Association pavilion. Here, Yuyu Pharma will introduce a range of its export products, which include the modified new drug Maxmarvil EC Tablet, Yuhylyx soft capsules, Yuvaro, and Senuvela Tab, among others. These products are a testament to Yuyu’s dedication to offering innovative healthcare solutions to a global audience.
A particular highlight of Yuyu Pharma’s presence at CPHI Worldwide will be the promotion of projects currently under development. This includes a reduced-sized Dutasteride and Dutasteride-Tamsulosin combination drug. These projects are strategically designed to facilitate the company’s entry into the U.S. and European markets, with a specific focus on addressing Benign Prostate Hyperplasia.
Danny Kang, Export Manager at Yuyu Pharma, expressed the company’s enthusiasm for the event, stating, “As always, we look forward to having active discussions with partners at our CPHI booth. And hope to meet new potential partners as well.” Yuyu Pharma aims to foster collaborations that will further enhance its global footprint and continue its mission of improving healthcare and well-being for individuals worldwide.
With a legacy of over eight decades in the healthcare sector, Yuyu Pharma (KRX: 000220) stands as a rapidly expanding global pharmaceutical company. By leveraging its expertise and innovative products, Yuyu Pharma is committed to contributing to the betterment of people’s lives through pioneering healthcare solutions.
For more information about Yuyu Pharma and its participation in CPHI Worldwide 2023, please visit the official Yuyu Pharma website or contact their team directly.
Related posts:
Otsuka Ventures into Psychedelic Medicines with Mindset Pharma Acquisition
Zealand Pharma’s Amylin Analog ZP8396 Shows Promise for Overcoming Obesity Challenges
Bayer Slashes 2023 Sales Forcast By 2.5 Billion Euros
Intercept Pharma Accepts Alfasigma’s $800 million Buyout Offer After FDA Rejections for NASH Therapy
